Perceptive Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$28.9M Sell
2,510,441
-157,000
-6% -$2.19M 0.5% 38
2026
Q2
$39.9M Buy
2,667,441
+375,000
+16% +$5.2M 0.6% 36
2026
Q1
$33.5M Buy
2,292,441
+1,600,000
+231% +$25.5M 0.66% 35
2025
Q4
$5.33M Sell
692,441
-746,154
-52% -$5.88M 0.1% 93
2025
Q3
$10.6M Hold
1,438,595
– – 0.31% 55
2025
Q2
$5.75M Buy
+1,438,595
New +$5.23M 0.21% 64

Other funds holding CRVS

Perceptive Advisors's CRVS Position: Q3 2026 in Review

Perceptive Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 5.9% in Q3 2026, selling an estimated $2.19M and leaving 2,510,441 shares worth $28.9M. The position accounts for 0.5% of the portfolio, ranked #38.

Perceptive Advisors first reported a position in CRVS in Q2 2025 and has held it in 6 quarters since. The position peaked at $39.9M in Q2 2026. 175 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Perceptive Advisors held 2,510,441 shares of Corvus Pharmaceuticals worth $28.9M as of Q3 2026.
  • Perceptive Advisors sold 157,000 Corvus Pharmaceuticals shares in Q3 2026, an estimated $2.19M.
  • Corvus Pharmaceuticals made up 0.5% of Perceptive Advisors's portfolio in Q3 2026, its #38 holding.
  • Perceptive Advisors first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Perceptive Advisors's Corvus Pharmaceuticals position peaked at $39.9M in Q2 2026.
  • 175 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Perceptive Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.